Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novartis beats Q4 earnings consensus
Novartis Ag (NVS) Q4 2024 Earnings Call Transcript
Good morning and good afternoon, and welcome to the Novartis Q4 2024 results release conference call and live webcast. [Operator instructions] The conf
Novartis beats Q4 earnings consensus as drug sales surge
Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta exceeded forecasts.
Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
Novartis targets 5%+ annual sales growth through 2029
Novartis targets 5%+ annual sales growth through 2029 amid robust brand performance
Q4 2024 Management View CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and core operating income rising 29% in constant currency. For the full year,
Balanced Caution: Novartis’s Strong Q4 Performance Amidst Growth Uncertainties
J.P. Morgan analyst Richard Vosser has maintained their neutral stance on NOVN stock, giving a Hold rating today.Invest with Confidence:
Novartis Expects Further Profit, Growth After Key Drugs Boost Sales
Novartis expects profit and sales to grow further this year after beating analysts’ expectations, boosted by revenue from its key drugs.
8h
Novartis Q4 Earnings: Revenue And EPS Beat, CEO Dismisses Entresto Patent Expiration Worries
Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported ...
8h
Novartis reports Q4 core EPS $1.98 vs. $1.53 last year
Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...
4h
on MSN
Novartis has cash for a big pharma deal—but here’s why it’s not buying
Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...
11h
Novartis CEO says U.S. exit from global health programmes to affect millions
The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...
6h
Novartis Q4 Core EPS Beats Market, Hikes Dividend; Sees Growth In FY25; Stock Up
Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback